

Benedetta Mussolin

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/346257/benedetta-mussolin-publications-by-year.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

22 papers	2,557 citations	17 h-index	24 g-index
24 ext. papers	3,288 ext. citations	16.6 avg, IF	4 L-index

#	Paper	IF	Citations
22	EGFR Amplification in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 1561-1569	9.7	3
21	A pilot study of next generation sequencing-liquid biopsy on cell-free DNA as a novel non-invasive diagnostic tool for Klippel-Trenaunay syndrome. <i>Vascular</i> , 2021 , 29, 85-91	1.3	6
20	TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors. <i>Cancer Discovery</i> , 2021 , 11, 126-141	24.4	15
19	EGFR Blockade Reverts Resistance to KRAS Inhibition in Colorectal Cancer. <i>Cancer Discovery</i> , 2020 , 10, 1129-1139	24.4	100
18	Multicenter Evaluation of Circulating Cell-Free DNA Extraction and Downstream Analyses for the Development of Standardized (Pre)analytical Work Flows. <i>Clinical Chemistry</i> , 2020 , 66, 149-160	5.5	51
17	A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology. <i>Clinical Colorectal Cancer</i> , 2019 , 18, 91-101.e3	3.8	15
16	High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib. <i>Frontiers in Oncology</i> , 2019 , 9, 622	5.3	17
15	Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients. <i>ESMO Open</i> , 2019 , 4,	6	12
14	Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer. <i>Cancer Cell</i> , 2018 , 34, 148-162.e7	24.3	77
13	Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies. <i>Nature Communications</i> , 2018 , 9, 2287	17.4	14
12	Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer. <i>Gut</i> , 2018 , 67, 1995-2005	19.2	119
11	Polyclonal Secondary Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma. <i>Cancer Discovery</i> , 2017 , 7, 252-263	24.4	262
10	Genetic Evolution of Glioblastoma Stem-Like Cells From Primary to Recurrent Tumor. <i>Stem Cells</i> , 2017 , 35, 2218-2228	5.8	30
9	Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. <i>Nature</i> , 2017 , 552, 116-120	50.4	290
8	Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases. <i>ESMO Open</i> , 2017 , 2, e000253	6	40
7	Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer. <i>British Journal of Cancer</i> , 2017 , 117, 347-352	8.7	22
6	MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations. <i>Science Translational Medicine</i> , 2016 , 8, 324ra14	17.5	61

5	Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. <i>Cancer Discovery</i> , 2016 , 6, 147-153	24.4	255
4	Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer. <i>Cancer Discovery</i> , 2016 , 6, 36-44	24.4	200
3	Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. <i>Nature Communications</i> , 2016 , 7, 13665	17.4	121
2	Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer. <i>Cancer Discovery</i> , 2015 , 5, 1271-81	24.4	126
1	Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. <i>Nature Medicine</i> , 2015 , 21, 795-801	50.5	557